Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VR-AD-1011
- Development stage
- Unknown
- Lead developer
- Hunazine Biotech
- Modality
- Small Molecules
01
Overview
VR-AD-1011 is a patented small molecule drug candidate being developed by Hunazine Biotech for the treatment of Inflammatory Bowel Disease (IBD). The drug is currently in Phase 2 clinical development, with trials reportedly conducted in regions including Bangladesh and Ghana. While the specific molecular mechanism of action and biological target have not been publicly disclosed, the molecule is positioned as a breakthrough treatment for IBD symptoms. Hunazine Biotech, a Spanish startup focused on gastrointestinal conditions in developing countries, holds an exclusive global license for the development and commercialization of this candidate.
Beyond the preview
Go deeper on VR-AD-1011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VR-AD-1011.